Current concepts of 131I therapy in oncology: Indications, methods and follow up [PDF]
Archive of Oncology, 2006 Radioiodine in various forms (as sodium iodide and as the iodinated compounds MIBG, LIPIODOL, et al.) has been used as a therapeutic agent in oncology. Differentiated thyroid carcinoma (DTC) has been successfully treated by 131I therapy.
Mihailović Jasna
doaj +1 more source
Gut microbiota: A novel and potential target for radioimmunotherapy in colorectal cancer
Frontiers in Immunology, 2023 Colorectal cancer (CRC) is one of the most common cancers, with a high mortality rate, and is a major burden on human health worldwide. Gut microbiota regulate human immunity and metabolism through producing numerous metabolites, which act as signaling ...
Hanghang Yuan +6 more
doaj +1 more source
World Journal of Nuclear Medicine, 2012 A Standard Operating Procedure (SOP) has been formulated for in-house preparation, quality control, dispensing and administration of 131 I-rituximab appropriate for the safe, effective, radioimmunotherapy of non-Hodgkin lymphoma.
Matthew Pickford, J. Turner
doaj +1 more source
Excitation functions of proton induced nuclear reactions on natW up to 40 MeV [PDF]
, 2007 Excitation functions for the production of the 181,182m,182g,183,184g,186Re and 183,184Ta radionuclides from proton bombardment on natural tungsten were measured using the stacked-foil activation technique for the proton energies up to 40 MeV. A new data
Akkermans +40 more
core +2 more sources
Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy? [PDF]
European Journal of Nuclear Medicine and Molecular Imaging, 2013 The clinical efficacy of radioimmunotherapy (RIT) has been clearly documented in the consolidation situation, such as first-line treatment of indolent non-Hodgkin lymphoma after induction chemotherapy [1] or after salvage resection of liver metastases from colon carcinoma [2], when tumour targets have a small, preferably microscopic, size. Efficacy has
Caroline, Rousseau +3 more
openaire +2 more sources
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates [PDF]
, 2015 Purpose: GPA33 is a colorectal cancer (CRC) antigen with unique retention properties after huA33-mediated tumor targeting. We tested a pretargeted radioimmunotherapy (PRIT) approach for CRC using a tetravalent bispecific antibody with dual specificity ...
Carrasquillo, Jorge A. +14 more
core +1 more source
RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES
Сибирский онкологический журнал, 2016 This review presents information about one of the promising areas of targeted therapy in modern oncology, which is called radioimmunotherapy. Particular attention is paid to the possibility of clinical application of this type of systemic treatment for ...
V. I. Chernov +4 more
doaj +1 more source
Frontiers in Oncology, 2021 The prognosis of advanced malignant tumors is very poor, and effective treatment is limited. Radioimmunotherapy (RIT) is a novel treatment method. However, its anti-tumor effect is relatively low in solid tumors, which is mainly due to the blood-tumor ...
Binwei Lin +9 more
doaj +1 more source
Radioimmunotherapy: A novel treatment of non-Hodgkin lymphoma [PDF]
Archive of Oncology, 2010 90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar) are current choices for radioimmunotherapy (RIT) of patients with follicular rituximab-relapsed or refractory CD20+ follicular B-cell NHL.
Petrović Tomislav, Mihailović Jasna
doaj +1 more source
Comparison of I-131 Radioimmunotherapy Tumor Dosimetry: Unit Density Sphere Model Versus Patient-Specific Monte Carlo Calculations [PDF]
, 2011 High computational requirements restrict the use of Monte Carlo algorithms for dose estimation in a clinical setting, despite the fact that they are considered more accurate than traditional methods.
Bolch WE +13 more
core +1 more source